NCT04985760View on ClinicalTrials.gov

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

November 28, 2025

Conditions
HIV Infections
Interventions
BIOLOGICAL

Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant

Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent

BIOLOGICAL

Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant

Volume matched control for Trimer 4571 vaccine 100mcg

BIOLOGICAL

Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant

Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent

BIOLOGICAL

Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant

Volume matched control for Trimer 4571 vaccine 500mcg

Trial Locations (2)

15213

University of Pittsburgh, Pittsburgh

43210

AIDS Clinical Trials Unit/The Ohio State University, Columbus

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Madhu Chhanda Choudhary

OTHER